Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers are comparing IMA203 cellular therapy with standard treatment in people with melanoma of the skin. Their melanoma is inoperable (cannot be surgically removed) or metastatic (has spread) and keeps growing despite treatment.
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
Researchers are comparing bone marrow transplantation to maintenance chemotherapy as post-induction treatment in older people with acute myeloid leukemia (AML) in remission. The people in this study are 65 or older and already had azacitidine and venetoclax as induction treatment.
Atezolizumab is a standard treatment for extensive-stage small cell lung cancer (SCLC, cancer which has spread). Researchers want to see if adding valemetostat to atezolizumab therapy is safe for people with SCLC. The people in this study have extensive-stage SCLC and have completed 4 treatment cycles of atezolizumab with chemotherapy.
The purpose of this study is to find the best dose of AZD0120 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Atezolizumab and durvalumab are standard drugs used to treat small cell lung cancer (SCLC). Researchers want to see if adding iadademstat to standard treatment helps slow SCLC growth longer than standard immunotherapies alone. The people in this study have SCLC that spread outside the lung or to other parts of the body.
Researchers want to find the best dose of ADCLEC.syn1 that can be used in people with leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even after treatment. There are currently no FDA-approved CAR T cell therapies for AML.
